Citations (105)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Qun Zhou, Shengsong Tang, Xianhui Zhang & Linxi Chen. (2021) Targeting PRAS40: a novel therapeutic strategy for human diseases. Journal of Drug Targeting 29:7, pages 703-715.
Read now
Read now
Aziz ur Rehman Aziz, Sumbal Farid, Kairong Qin, Hanqin Wang & Bo Liu. (2020) Regulation of insulin resistance and glucose metabolism by interaction of PIM kinases and insulin receptor substrates. Archives of Physiology and Biochemistry 126:2, pages 129-138.
Read now
Read now
Jiacong Guo, Priyamvada Jayaprakash, Jian Dan, Petra Wise, Gyu-Beom Jang, Chengyu Liang, Mei Chen, David T. Woodley, Muller Fabbri & Wei Li. (2017) PRAS40 Connects Microenvironmental Stress Signaling to Exosome-Mediated Secretion. Molecular and Cellular Biology 37:19.
Read now
Read now
Lisa S. Chen, Ji-Yeon Yang, Han Liang, Jorge E. Cortes & Varsha Gandhi. (2016) Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leukemia & Lymphoma 57:12, pages 2863-2873.
Read now
Read now
Priyanka Sharma, Anoop Saraya, Prerna Gupta & Rinu Sharma. (2013) Decreased levels of circulating and tissue miR-107 in human esophageal cancer. Biomarkers 18:4, pages 322-330.
Read now
Read now
Anna Lena Merkel, Eric Meggers & Matthias Ocker. (2012) PIM1 kinase as a target for cancer therapy. Expert Opinion on Investigational Drugs 21:4, pages 425-436.
Read now
Read now
Yesid Alvarado, Francis J Giles & Ronan T Swords. (2012) The PIM kinases in hematological cancers. Expert Review of Hematology 5:1, pages 81-96.
Read now
Read now
Bruno Vincenzi, Andrea Napolitano, Loretta D'Onofrio, Anna Maria Frezza, Marianna Silletta, Olga Venditti, Daniele Santini & Giuseppe Tonini. (2011) Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside. Expert Opinion on Investigational Drugs 20:12, pages 1685-1705.
Read now
Read now
Sébastien Albert, Maria Serova, Chantal Dreyer, Marie-Paule Sablin, Sandrine Faivre & Eric Raymond. (2010) New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opinion on Investigational Drugs 19:8, pages 919-930.
Read now
Read now
Articles from other publishers (96)
Marcia Bellon & Christophe Nicot. (2023) Targeting Pim kinases in hematological cancers: molecular and clinical review. Molecular Cancer 22:1.
Crossref
Crossref
Le Yu, Jessica Wei & Pengda Liu. (2022) Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Seminars in Cancer Biology 85, pages 69-94.
Crossref
Crossref
Tapan Behl, Arpita Arora, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Saurabh Bhatia, Ahmed Al-Harrasi, Simona Bungau & Ebrahim Mostafavi. (2022) Molecular and Biochemical Pathways Encompassing Diabetes Mellitus
and Dementia. CNS & Neurological Disorders - Drug Targets 21:7, pages 542-556.
Crossref
Crossref
Giri R. Gnawali, Koichi Okumura, Karolina Perez, Rosa Gallagher, Julia Wulfkuhle, Emanuel F. Petricoin, Sathish Kumar Reddy Padi, Jeremiah Bearss, Zhiyong He, Wei Wang & Andrew S. Kraft. (2022) Synthesis of 2-oxoquinoline derivatives as dual pim and mTORC protein kinase inhibitors. Medicinal Chemistry Research 31:7, pages 1154-1175.
Crossref
Crossref
Kristin M. Zimmerman Savill, Brian B. Lee, Jason Oeh, Jie Lin, Eva Lin, Wei-Jen Chung, Amy Young, Wennie Chen, Monika Miś, Kathryn Mesh, Jeffrey Eastham, Florian Gnad, Zhaoshi Jiang, Eric W. Stawiski, Benjamin Haley, Anneleen Daemen, Xiaojing Wang, Hartmut Koeppen, Zora Modrusan, Scott E. Martin, Deepak Sampath & Kui Lin. (2022) Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors. Nature Communications 13:1.
Crossref
Crossref
Youyi Zhao, Aziz ur Rehman Aziz, Hangyu Zhang, Zhengyao Zhang, Na Li & Bo Liu. (2022) A systematic review on active sites and functions of PIM-1 protein. Human Cell 35:2, pages 427-440.
Crossref
Crossref
Tianhua Zhang, Yuzhen Wang, Hongjiu Yu, Ting Zhang, Lianying Guo, Jie Xu, Xiaoqing Wei, Ning Wang, Yingjie Wu, Xiuli Wang & Lin Huang. (2022) PGK1 represses autophagy-mediated cell death to promote the proliferation of liver cancer cells by phosphorylating PRAS40. Cell Death & Disease 13:1.
Crossref
Crossref
Aanchal Rathi, Dhiraj Kumar, Gulam Mustafa Hasan, Mohammad Mahfuzul Haque & Md Imtaiyaz Hassan. (2021) Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects. Biochimica et Biophysica Acta (BBA) - General Subjects 1865:11, pages 129995.
Crossref
Crossref
Gillian Moore, Clara Lightner, Samira Elbai, Lauren Brady, Siobhan Nicholson, Ronan Ryan, Katie E. O’Sullivan, Kenneth J. O’Byrne, Carmen Blanco-Aparicio, Sinead Cuffe, Michael O’Neill, Susan Heavey, Stephen P. Finn & Kathy Gately. (2021) Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC. Cancers 13:9, pages 2139.
Crossref
Crossref
Jeremiah J Bearss, Sathish KR Padi, Neha Singh, Marina Cardo‐Vila, Jin H Song, Ghassan Mouneimne, Nikita Fernandes, Yang Li, Matthew R Harter, Jaime MC Gard, Anne E Cress, Wolfgang Peti, Andrew DL Nelson, J Ross Buchan, Andrew S Kraft & Koichi Okumura. (2021) EDC3 phosphorylation regulates growth and invasion through controlling P‐body formation and dynamics. EMBO reports 22:4.
Crossref
Crossref
Yamini M. Ohol, Michael T. Sun, Gene Cutler, Paul R. Leger, Dennis X. Hu, Berenger Biannic, Payal Rana, Cynthia Cho, Scott Jacobson, Steve T. Wong, Jerick Sanchez, Niket Shah, Deepa Pookot, Betty Abraham, Kyle Young, Silpa Suthram, Lisa A. Marshall, Delia Bradford, Nathan Kozon, Xinping Han, Akinori Okano, Jack Maung, Christophe Colas, Jacob Schwarz, David Wustrow, Dirk G. Brockstedt & Paul D. Kassner. (2020)
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity
In Vitro
and
In Vivo
. Molecular Cancer Therapeutics 19:10, pages 1970-1980.
Crossref
Crossref
Salihanur Darici, Hazem Alkhaldi, Gillian Horne, Heather G. Jørgensen, Sandra Marmiroli & Xu Huang. (2020) Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. Journal of Clinical Medicine 9:9, pages 2934.
Crossref
Crossref
James T. Lim, Neha Singh, Libia A. Leuvano, Valerie S. Calvert, Emanuel F. Petricoin, David T. Teachey, Richard B. Lock, Megha Padi, Andrew S. Kraft & Sathish K.R. Padi. (2020) PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis. Molecular Cancer Therapeutics 19:9, pages 1809-1821.
Crossref
Crossref
Sabina Luszczak, Benjamin S. Simpson, Urszula Stopka-Farooqui, Vignesh Krishna Sathyadevan, Lina M. Carmona Echeverria, Christopher Kumar, Helena Costa, Aiman Haider, Alex Freeman, Charles Jameson, Marzena Ratynska, Imen Ben-Salha, Ashwin Sridhar, Greg Shaw, John D. Kelly, Hayley Pye, Kathy A. Gately, Hayley C. Whitaker & Susan Heavey. (2020) Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer. Scientific Reports 10:1.
Crossref
Crossref
Renate De SmedtJulie MorscioLindy ReunesJuliette Roels, Valentina BardelliBeatrice LintermansWouter Van LoockeAfonso AlmeidaLaurence C. CheungRishi S. Kotecha, Marc R. MansourAnne Uyttebroeck, Peter Vandenberghe, Roberta La StarzaCristina MecucciTim Lammens, Nadine Van RoyBarbara De Moerloose, João T. BarataTom TaghonSteven Goossens & Pieter Van Vlierberghe. (2020) Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. Blood 135:19, pages 1685-1695.
Crossref
Crossref
Lacey M. Litchfield, Karsten Boehnke, Manisha Brahmachary, Cecilia Mur, Chen Bi, Jennifer R. Stephens, J. Michael Sauder, Sonia M. Gutiérrez, Ann M. McNulty, Xiang S. Ye, Wenjuan Wu, María José Lallena, Xueqian Gong, Farhana F. Merzoug, Valerie M. Jansen & Sean G. Buchanan. (2020) Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells. Oncotarget 11:17, pages 1478-1492.
Crossref
Crossref
Sean P. Kennedy, Michael O’Neill, Darren Cunningham, Patrick G. Morris, Sinead Toomey, Carmen Blanco-Aparicio, Sonia Martinez, Joaquin Pastor, Alex J. Eustace & Bryan T. Hennessy. (2020) Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer. Oncogene 39:14, pages 3028-3040.
Crossref
Crossref
Marie-Claude LampronGéraldine VitryValérie NadeauYann GrobsRenée ParadisNolwenn SamsonÈve TremblayOlivier BoucheratJolyane MelocheSébastien BonnetSteeve ProvencherFrançois PotusRoxane Paulin. (2020) PIM1 (Moloney Murine Leukemia Provirus Integration Site) Inhibition Decreases the Nonhomologous End-Joining DNA Damage Repair Signaling Pathway in Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology 40:3, pages 783-801.
Crossref
Crossref
Hui Yi Chew, Priscila O. De Lima, Jazmina L. Gonzalez Cruz, Blerida Banushi, Godwins Echejoh, Lingbo Hu, Shannon R. Joseph, Benedict Lum, James Rae, Jake S. O’Donnell, Lilia Merida de Long, Satomi Okano, Brigid King, Rachael Barry, Davide Moi, Roberta Mazzieri, Ranjeny Thomas, Fernando Souza-Fonseca-Guimaraes, Matthew Foote, Adam McCluskey, Phillip J. Robinson, Ian H. Frazer, Nicholas A. Saunders, Robert G. Parton, Riccardo Dolcetti, Katharine Cuff, Jennifer H. Martin, Benedict Panizza, Euan Walpole, James W. Wells & Fiona Simpson. (2020) Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. Cell 180:5, pages 895-914.e27.
Crossref
Crossref
Sabina Luszczak, Christopher Kumar, Vignesh Krishna Sathyadevan, Benjamin S. Simpson, Kathy A. Gately, Hayley C. Whitaker & Susan Heavey. (2020) PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer. Signal Transduction and Targeted Therapy 5:1.
Crossref
Crossref
Yuanshuai Zhou, Zhongjuan Xu, Yanzhen Yu, Junjun Cao, Yong Qiao, Hong Qiao & Guangli Suo. (2019) Comprehensive analysis of the lncRNA-associated ceRNA network identifies neuroinflammation biomarkers for Alzheimer's disease. Molecular Omics 15:6, pages 459-469.
Crossref
Crossref
Ricky M. Trigg, Liam C. Lee, Nina Prokoph, Leila Jahangiri, C. Patrick Reynolds, G. A. Amos Burke, Nicola A. Probst, Miaojun Han, Jamie D. Matthews, Hong Kai Lim, Eleanor Manners, Sonia Martinez, Joaquin Pastor, Carmen Blanco-Aparicio, Olaf Merkel, Ines Garces de los Fayos Alonso, Petra Kodajova, Simone Tangermann, Sandra Högler, Ji Luo, Lukas Kenner & Suzanne D. Turner. (2019) The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status. Nature Communications 10:1.
Crossref
Crossref
Lucia Mazzacurati, Robert J. Collins, Garima Pandey, Que T. Lambert-Showers, Narmin E. Amin, Ling Zhang, Matthew C. Stubbs, Pearlie K. Epling-Burnette, Holly K. Koblish & Gary W. Reuther. (2019) The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN. Blood Advances 3:22, pages 3503-3514.
Crossref
Crossref
Watanabe, Nogami, Okada, Akiyama, Umezawa & Miura. (2019) FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM. Cancers 11:12, pages 1827.
Crossref
Crossref
Sathish K. R. PadiNeha SinghJeremiah J. BearssVirginie OliveJin H. SongMarina Cardó-VilaAndrew S. KraftKoichi Okumura. (2019) Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth. Proceedings of the National Academy of Sciences 116:41, pages 20505-20510.
Crossref
Crossref
Tejaswini Subbannayya, Pamela Leal-Rojas, Alex Zhavoronkov, Ivan V. Ozerov, Mikhail Korzinkin, Niraj Babu, Aneesha Radhakrishnan, Sandip Chavan, Remya Raja, Sneha M. Pinto, Arun H. Patil, Mustafa A. Barbhuiya, Prashant Kumar, Rafael Guerrero-Preston, Sanjay Navani, Pramod K. Tiwari, Rekha Vijay Kumar, T. S. Keshava Prasad, Juan Carlos Roa, Akhilesh Pandey, David Sidransky, Harsha Gowda, Evgeny Izumchenko & Aditi Chatterjee. (2019) PIM1 kinase promotes gallbladder cancer cell proliferation via inhibition of proline-rich Akt substrate of 40 kDa (PRAS40). Journal of Cell Communication and Signaling 13:2, pages 163-177.
Crossref
Crossref
Matthias Beyens, Timon Vandamme, Marc Peeters, Guy Van Camp & Ken Op de Beeck. (2019) Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors. Endocrine-Related Cancer 26:3, pages R109-R130.
Crossref
Crossref
J. Remy, B. Linder, U. Weirauch, J. Konovalova, R. Marschalek, A. Aigner & D. Kögel. (2019) Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1866:2, pages 175-189.
Crossref
Crossref
Anil Yadav, Vinoth Kumar, David Bailey & Byeong-Churl Jang. (2019) AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK. International Journal of Molecular Sciences 20:2, pages 363.
Crossref
Crossref
You-Jung Ha, Yong Seok Choi, Dong Woo Han, Eun Ha Kang, In Seol Yoo, Jin Hyun Kim, Seong Wook Kang, Eun Young Lee, Yeong Wook Song & Yun Jong Lee. (2019) PIM-1 kinase is a novel regulator of proinflammatory cytokine-mediated responses in rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology 58:1, pages 154-164.
Crossref
Crossref
Vadim Lincoln, Xin Tang, Mei Chen & Wei Li. 2019. Heat Shock Proteins in Signaling Pathways. Heat Shock Proteins in Signaling Pathways
289
315
.
Valentina Minieri, Marco De Dominici, Patrizia Porazzi, Samanta A. Mariani, Orietta Spinelli, Alessandro Rambaldi, Luke F. Peterson, Pierluigi Porcu, Marja T. Nevalainen & Bruno Calabretta. (2018) Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia. Cancer Research 78:20, pages 5793-5807.
Crossref
Crossref
Emilia Białopiotrowicz, Patryk Górniak, Monika Noyszewska‐Kania, Bartosz Puła, Hanna Makuch‐Łasica, Grażyna Nowak, Aleksandra Bluszcz, Maciej Szydłowski, Ewa Jabłonska, Karolina Piechna, Tomasz Sewastianik, Anna Polak, Ewa Lech‐Marańda, Bożena K. Budziszewska, Maja Wasylecka‐Juszczyńska, Katarzyna Borg, Krzysztof Warzocha, Wojciech Czardybon, Michał Gałęzowski, Renata Windak, Krzysztof Brzózka & Przemysław Juszczyński. (2018)
Microenvironment‐induced
PIM
kinases promote
CXCR
4‐triggered
mTOR
pathway required for chronic lymphocytic leukaemia cell migration
. Journal of Cellular and Molecular Medicine 22:7, pages 3548-3559.
Crossref
Crossref
Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa, Keigo Okada, Ayako Nogami, Gaku Oshikawa, Toshikage Nagao & Osamu Miura. (2018) Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2. Oncotarget 9:42, pages 26834-26851.
Crossref
Crossref
Diede Brunen, Romy C. de Vries, Cor Lieftink, Roderick L. Beijersbergen & René Bernards. (2018) PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma. Molecular Cancer Therapeutics 17:4, pages 849-857.
Crossref
Crossref
Wojciech Czardybon, Renata Windak, Aniela Gołas, Michał Gałęzowski, Aleksandra Sabiniarz, Izabela Dolata, Magdalena Salwińska, Paweł Guzik, Magdalena Zawadzka, Ewelina Gabor-Worwa, Bożena Winnik, Małgorzata Żurawska, Ewa Kolasińska, Ewelina Wincza, Marta Bugaj, Monika Danielewicz, Eliza Majewska, Milena Mazan, Grzegorz Dubin, Monika Noyszewska-Kania, Ewa Jabłońska, Maciej Szydłowski, Tomasz Sewastianik, Bartosz Puła, Anna Szumera-Ciećkiewicz, Monika Prochorec-Sobieszek, Elżbieta Mądro, Ewa Lech-Marańda, Krzysztof Warzocha, Jerome Tamburini, Przemysław Juszczyński & Krzysztof Brzózka. (2018) A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget 9:24, pages 16917-16931.
Crossref
Crossref
Noelia Puente-Moncada, Paula Costales, Isaac Antolín, Luz-Elena Núñez, Patricia Oro, Maria Ana Hermosilla, Jhudit Pérez-Escuredo, Nicolás Ríos-Lombardía, Ana M. Sanchez-Sanchez, Elisa Luño, Carmen Rodríguez, Vanesa Martín & Francisco Morís. (2018) Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia. Molecular Cancer Therapeutics 17:3, pages 614-624.
Crossref
Crossref
Wen-ting Dai, Yi-xuan Zou, Robin R. White, Jian-xin Liu & Hong-yun Liu. (2017) Transcriptomic profiles of the bovine mammary gland during lactation and the dry period. Functional & Integrative Genomics 18:2, pages 125-140.
Crossref
Crossref
Keigo Okada, Ayako Nogami, Shinya Ishida, Hiroki Akiyama, Cheng Chen, Yoshihiro Umezawa & Osamu Miura. (2017) FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway. Oncotarget 9:10, pages 8870-8886.
Crossref
Crossref
Richard J. Rebello, Alisée V. Huglo & Luc Furic. (2018) PIM activity in tumours: A key node of therapy resistance. Advances in Biological Regulation 67, pages 163-169.
Crossref
Crossref
Fabio Di Domenico, Antonella Tramutola, Cesira Foppoli, Elizabeth Head, Marzia Perluigi & D. Allan Butterfield. (2018) mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia. Free Radical Biology and Medicine 114, pages 94-101.
Crossref
Crossref
Ilana Kelsey, Marie Zbinden, Vanessa Byles, Margaret Torrence & Brendan D. Manning. (2017) mTORC1 suppresses PIM3 expression via miR-33 encoded by the SREBP loci. Scientific Reports 7:1.
Crossref
Crossref
Dan Lv, Lianying Guo, Ting Zhang & Lin Huang. (2017) PRAS40 signaling in tumor. Oncotarget 8:40, pages 69076-69085.
Crossref
Crossref
Sathish K.R. Padi, Libia A. Luevano, Ningfei An, Ritu Pandey, Neha Singh, Jin H. Song, Jon C. Aster, Xue-Zhong Yu, Shikhar Mehrotra & Andrew S. Kraft. (2017) Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. Oncotarget 8:18, pages 30199-30216.
Crossref
Crossref
Jinhua Wu, Qin Zhang, Yen-Ruh Wuu, Sirui Zou & Tom K. Hei. (2017) Cytoplasmic Irradiation Induces Metabolic Shift in Human Small Airway Epithelial Cells via Activation of Pim-1 Kinase. Radiation Research 187:4, pages 451-463.
Crossref
Crossref
I. Duran, J. Lambea, P. Maroto, J. L. González-Larriba, Luis Flores, S. Granados-Principal, M. Graupera, B. Sáez, A. Vivancos & O. Casanovas. (2016) Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action. Targeted Oncology 12:1, pages 19-35.
Crossref
Crossref
Hyun-Jung YuSeong-Ho Koh. (2017) The role of PI3K/AKT pathway and its therapeutic possibility in Alzheimer's disease. Hanyang Medical Reviews 37:1, pages 18.
Crossref
Crossref
Ningfei An, Bo Cen, Houjian Cai, Jin H. Song, Andrew Kraft & Yubin Kang. (2016) Pim1 kinase regulates c-Kit gene translation. Experimental Hematology & Oncology 5:1.
Crossref
Crossref
Jianwei Xu, Guangbing Xiong, Zhe Cao, Hua Huang, Tianxiao Wang, Lei You, Li Zhou, Lianfang Zheng, Ya Hu, Taiping Zhang & Yupei Zhao. (2016) PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value. Journal of Experimental & Clinical Cancer Research 35:1.
Crossref
Crossref
Ramon Velazquez, Darren M. Shaw, Antonella Caccamo & Salvatore Oddo. (2016) Pim1 inhibition as a novel therapeutic strategy for Alzheimer’s disease. Molecular Neurodegeneration 11:1.
Crossref
Crossref
Ryan E. Henry, Evan R. Barry, Lillian Castriotta, Brendon Ladd, Aleksandra Markovets, Garry Beran, Yongxin Ren, Feng Zhou, Ammar Adam, Michael Zinda, Corinne Reimer, Weiguo Qing, Weiguo Su, Edwin Clark, Celina M. D'Cruz & Alwin G. Schuller. (2016) Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation. Oncotarget 7:36, pages 57651-57670.
Crossref
Crossref
Zhao Zhong Chong. (2016) Targeting PRAS40 for multiple diseases. Drug Discovery Today 21:8, pages 1222-1231.
Crossref
Crossref
Danni Deng, Lei Wang, Yao Chen, Bowen Li, Lian Xue, Naiyuan Shao, Qiang Wang, Xiwei Xia, Yilin Yang & Feng Zhi. (2016) MicroRNA‐124‐3p regulates cell proliferation, invasion, apoptosis, and bioenergetics by targeting PIM1 in astrocytoma. Cancer Science 107:7, pages 899-907.
Crossref
Crossref
Diede Brunen, María José García-Barchino, Disha Malani, Noorjahan Jagalur Basheer, Cor Lieftink, Roderick L. Beijersbergen, Astrid Murumägi, Kimmo Porkka, Maija Wolf, C. Michel Zwaan, Maarten Fornerod, Olli Kallioniemi, José Ángel Martínez-Climent & René Bernards. (2016) Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling. Oncotarget 7:25, pages 37407-37419.
Crossref
Crossref
Asneha Iqbal, Frank Eckerdt, Jonathan Bell, Ichiro Nakano, Francis J. Giles, Shi-Yuan Cheng, Rishi R. Lulla, Stewart Goldman & Leonidas C. Platanias. (2016) Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition. Oncotarget 7:22, pages 33192-33201.
Crossref
Crossref
Falguni DasNandini Ghosh-Choudhury, Meenalakshmi M. MariappanBalakuntalam S. KasinathGoutam Ghosh Choudhury. (2016) Hydrophobic motif site-phosphorylated protein kinase CβII between mTORC2 and Akt regulates high glucose-induced mesangial cell hypertrophy. American Journal of Physiology-Cell Physiology 310:7, pages C583-C596.
Crossref
Crossref
Monica Pallis, Tamsin Harvey & Nigel Russell. (2016) Phenotypically Dormant and Immature Leukaemia Cells Display Increased Ribosomal Protein S6 Phosphorylation. PLOS ONE 11:3, pages e0151480.
Crossref
Crossref
Scott A. Ezell, Suping Wang, Teeru Bihani, Zhongwu Lai, Shaun E. Grosskurth, Suprawee Tepsuporn, Barry R. Davies, Dennis Huszar & Kate F. Byth. (2016) Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma. Oncotarget 7:8, pages 9163-9174.
Crossref
Crossref
Marc Francaux, Bénédicte Demeulder, Damien Naslain, Raphael Fortin, Olivier Lutz, Gilles Caty & Louise Deldicque. (2016) Aging Reduces the Activation of the mTORC1 Pathway after Resistance Exercise and Protein Intake in Human Skeletal Muscle: Potential Role of REDD1 and Impaired Anabolic Sensitivity. Nutrients 8:1, pages 47.
Crossref
Crossref
Arnaud Francois, Julie Verite, Agnès Rioux Bilan, Thierry Janet, Frédéric Calon, Bernard Fauconneau, Marc Paccalin & Guylène Page. 2016. Molecules to Medicine with mTOR. Molecules to Medicine with mTOR
85
104
.
Dany A. Curi, Elspeth M. Beauchamp, Gavin T. Blyth, Ahmet Dirim Arslan, Nicholas J. Donato, Francis J. Giles, Jessica K. Altman & Leonidas C. Platanias. (2015) Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias. Oncotarget 6:32, pages 33206-33216.
Crossref
Crossref
Noel A. Warfel & Andrew S. Kraft. (2015) PIM kinase (and Akt) biology and signaling in tumors. Pharmacology & Therapeutics 151, pages 41-49.
Crossref
Crossref
Ritu Malla, Charles R. AshbyJr.Jr., Narayanan K. Narayanan, Bhagavathi Narayanan, Jesika S. Faridi & Amit K. Tiwari. (2015) Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer. Biochemical and Biophysical Research Communications 463:3, pages 161-166.
Crossref
Crossref
Kaitlen Samse, Jacqueline Emathinger, Nirmala Hariharan, Pearl Quijada, Kelli Ilves, Mirko Völkers, Lucia Ormachea, Andrea De La Torre, Amabel M. Orogo, Roberto Alvarez, Shabana Din, Sadia Mohsin, Megan Monsanto, Kimberlee M. Fischer, Walter P. Dembitsky, Åsa B. Gustafsson & Mark A. Sussman. (2015) Functional Effect of Pim1 Depends upon Intracellular Localization in Human Cardiac Progenitor Cells. Journal of Biological Chemistry 290:22, pages 13935-13947.
Crossref
Crossref
Ayako Nogami, Gaku Oshikawa, Keigo Okada, Shusaku Fukutake, Yoshihiro Umezawa, Toshikage Nagao, Tetsuya Kurosu & Osamu Miura. (2015) FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia. Oncotarget 6:11, pages 9189-9205.
Crossref
Crossref
Susann Herzog, Matthias Alexander Fink, Kerstin Weitmann, Claudius Friedel, Stefan Hadlich, Sönke Langner, Katharina Kindermann, Tobias Holm, Andreas Böhm, Eskil Eskilsson, Hrvoje Miletic, Markus Hildner, Michael Fritsch, Silke Vogelgesang, Christoph Havemann, Christoph Alexander Ritter, Henriette Elisabeth Meyer zu Schwabedissen, Bernhard Rauch, Wolfgang Hoffmann, Heyo Klaus Kroemer, Henry Schroeder & Sandra Bien-Möller. (2015) Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival. Neuro-Oncology 17:2, pages 223-242.
Crossref
Crossref
Bich Thuy Le, Malika Kumarasiri, Julian RJ Adams, Mingfeng Yu, Robert Milne, Matthew J Sykes & Shudong Wang. (2015) Targeting Pim kinases for cancer treatment: opportunities and challenges. Future Medicinal Chemistry 7:1, pages 35-53.
Crossref
Crossref
Marina Y. Zemskova, Jin H. Song, Bo Cen, Javier Cerda-Infante, Viviana P. Montecinos & Andrew S. Kraft. (2015) Regulation of prostate stromal fibroblasts by the PIM1 protein kinase. Cellular Signalling 27:1, pages 135-146.
Crossref
Crossref
Koremu Meja, Chloe Stengel, Rob Sellar, Dennis Huszar, Barry R. Davies, Rosemary E. Gale, David C. Linch & Asim Khwaja. (2014) PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways. British Journal of Haematology 167:1, pages 69-79.
Crossref
Crossref
CAMILLA EVANGELISTI, CECILIA EVANGELISTI, FRANCESCA CHIARINI, ANNALISA LONETTI, FRANCESCA BUONTEMPO, DANIELA BRESSANIN, ALESSANDRA CAPPELLINI, ESTER ORSINI, JAMES A. McCUBREY & ALBERTO M. MARTELLI. (2014) Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review). International Journal of Oncology 45:3, pages 909-918.
Crossref
Crossref
Jianwei Xu, Taiping Zhang, Tianxiao Wang, Lei You & Yupei Zhao. (2014) PIM kinases: an overview in tumors and recent advances in pancreatic cancer. Future Oncology 10:5, pages 865-876.
Crossref
Crossref
Matteo Santoni, Francesco Pantano, Consuelo Amantini, Massimo Nabissi, Alessandro Conti, Luciano Burattini, Alice Zoccoli, Rossana Berardi, Giorgio Santoni, Giuseppe Tonini, Daniele Santini & Stefano Cascinu. (2014) Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1845:2, pages 221-231.
Crossref
Crossref
Erika K. KeetonKristen McEachernKeith S. DillmanSangeetha PalakurthiYichen CaoMichael R. GrondineSurinder Kaur, Suping WangYuching ChenAllan WuMinhui ShenFrancis D. GibbonsMichelle L. LambXiaolan ZhengRichard M. Stone, Daniel J. DeAngelo, Leonidas C. Platanias, Les A. DakinHuawei ChenPaul D. LyneDennis Huszar. (2014) AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood 123:6, pages 905-913.
Crossref
Crossref
Maja Narlik-Grassow, Carmen Blanco-Aparicio & Amancio Carnero. (2014) The PIM Family of Serine/Threonine Kinases in Cancer. Medicinal Research Reviews 34:1, pages 136-159.
Crossref
Crossref
Ningfei An, Andrew S Kraft & Yubin Kang. (2013) Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. Journal of Hematology & Oncology 6:1.
Crossref
Crossref
Jing Lu, Tatiana Zavorotinskaya, Yumin Dai, Xiao-Hong Niu, Joseph Castillo, Janet Sim, Jianjun Yu, Yingyun Wang, John L. Langowski, Jocelyn Holash, Kevin Shannon & Pablo D. Garcia. (2013) Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood 122:9, pages 1610-1620.
Crossref
Crossref
Maja Narlik-Grassow, Carmen Blanco-Aparicio, Yolanda Cecilia, Marco Perez, Sandra Muñoz-Galvan, Marta Cañamero & Amancio Carnero. (2013) Conditional Transgenic Expression of PIM1 Kinase in Prostate Induces Inflammation-Dependent Neoplasia. PLoS ONE 8:4, pages e60277.
Crossref
Crossref
Carmen Blanco-Aparicio & Amancio Carnero. (2013) Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities. Biochemical Pharmacology 85:5, pages 629-643.
Crossref
Crossref
Thomas Walpen, Ina Kalus, Jürg Schwaller, Martin A. Peier, Edouard J. Battegay & Rok Humar. (2012) Nuclear PIM1 confers resistance to rapamycin-impaired endothelial proliferation. Biochemical and Biophysical Research Communications 429:1-2, pages 24-30.
Crossref
Crossref
James A. McCubrey, Linda S. Steelman, William H. Chappell, Stephen L. Abrams, Richard A. Franklin, Giuseppe Montalto, Melchiorre Cervello, Massimo Libra, Saverio Candido, Grazia Malaponte, Maria C. Mazzarino, Paolo Fagone, Ferdinando Nicoletti, Jörg Bäsecke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michele Milella, Agostino Tafuri, Francesca Chiarini, Camilla Evangelisti, Lucio Cocco & Alberto M. Martelli. (2012) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget 3:10, pages 1068-1111.
Crossref
Crossref
Warren Fiskus, Siddhartha Ganguly, Suman Kambhampati & Kapil N. Bhalla. (2012) Role of Additional Novel Therapies in Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America 26:5, pages 959-980.
Crossref
Crossref
Yanqing Xu, Amanda Parmar, Emmanuelle Roux, Alejandro Balbis, Victor Dumas, Stephanie Chevalier & Barry I. Posner. (2012) Epidermal Growth Factor-induced Vacuolar (H+)-ATPase Assembly. Journal of Biological Chemistry 287:31, pages 26409-26422.
Crossref
Crossref
Claudia Wiza, Emmani B. M. Nascimento & D. Margriet Ouwens. (2012) Role of PRAS40 in Akt and mTOR signaling in health and disease. American Journal of Physiology-Endocrinology and Metabolism 302:12, pages E1453-E1460.
Crossref
Crossref
Jui-Ling Hsu, Pui-Kei Leong, Yunn-Fang Ho, Lih-Ching Hsu, Pin-Hsuan Lu, Ching-Shih Chen & Jih-Hwa Guh. (2012) Pim-1 knockdown potentiates paclitaxel-induced apoptosis in human hormone-refractory prostate cancers through inhibition of NHEJ DNA repair. Cancer Letters 319:2, pages 214-222.
Crossref
Crossref
Cristina Pallares-Cartes, Gulcin Cakan-Akdogan & Aurelio A. Teleman. (2012) Tissue-Specific Coupling between Insulin/IGF and TORC1 Signaling via PRAS40 in Drosophila. Developmental Cell 22:1, pages 172-182.
Crossref
Crossref
Wanyeon Kim, HyeSook Youn, Ki Moon Seong, Hee Jung Yang, Young Ju Yun, TaeWoo Kwon, Young Ha Kim, Ji Young Lee, Young-Woo Jin & BuHyun Youn. (2011) PIM1-Activated PRAS40 Regulates Radioresistance in Non-small Cell Lung Cancer Cells through Interplay with FOXO3a, 14-3-3 and Protein Phosphatases. Radiation Research 176:5, pages 539.
Crossref
Crossref
Antonella Caccamo, Monica A. Maldonado, Smita Majumder, David X. Medina, Walter Holbein, Andrea Magrí & Salvatore Oddo. (2011) Naturally Secreted Amyloid-β Increases Mammalian Target of Rapamycin (mTOR) Activity via a PRAS40-mediated Mechanism. Journal of Biological Chemistry 286:11, pages 8924-8932.
Crossref
Crossref
Jennifer S. Carew, Kevin R. Kelly & Steffan T. Nawrocki. (2011) Mechanisms of mTOR inhibitor resistance in cancer therapy. Targeted Oncology 6:1, pages 17-27.
Crossref
Crossref
Zanna BeharrySandeep MahajanMarina Zemskova, Ying-Wei Lin, Baby G. TholanikunnelZuping XiaCharles D. SmithAndrew S. Kraft. (2010) The Pim protein kinases regulate energy metabolism and cell growth. Proceedings of the National Academy of Sciences 108:2, pages 528-533.
Crossref
Crossref
Martijn C. Nawijn, Andrej Alendar & Anton Berns. (2010) For better or for worse: the role of Pim oncogenes in tumorigenesis. Nature Reviews Cancer 11:1, pages 23-34.
Crossref
Crossref
Nirmalya Dey, Nandini Ghosh-Choudhury, Falguni Das, Xiaonan Li, Balachandar Venkatesan, Jeffrey L. Barnes, Balakuntalam S. Kasinath & Goutam Ghosh Choudhury. (2010) PRAS40 acts as a nodal regulator of high glucose-induced TORC1 activation in glomerular mesangial cell hypertrophy. Journal of Cellular Physiology 225:1, pages 27-41.
Crossref
Crossref
David C. McMullen & John M. Hallenbeck. (2010) Regulation of Akt during torpor in the hibernating ground squirrel, Ictidomys tridecemlineatus. Journal of Comparative Physiology B 180:6, pages 927-934.
Crossref
Crossref
G Guo, X Qiu, S Wang, Y Chen, P B Rothman, Z Wang, Y Chen, G Wang & J-L Chen. (2010) Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells. Oncogene 29:26, pages 3845-3853.
Crossref
Crossref
Ying-Wei LinZanna M. BeharryElizabeth G. HillJin H. SongWenxue WangZuping XiaZhenhua ZhangPeter D. AplanJon C. Aster, Charles D. SmithAndrew S. Kraft. (2010) A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 115:4, pages 824-833.
Crossref
Crossref
Xiaochun Bai & Yu Jiang. (2009) Key factors in mTOR regulation. Cellular and Molecular Life Sciences 67:2, pages 239-253.
Crossref
Crossref
Ly Q. Hong-Brown, C. Randell Brown, Abid A. Kazi, Danuta S. Huber, Anne M. Pruznak & Charles H. Lang. (2010) Alcohol and PRAS40 knockdown decrease mTOR activity and protein synthesis via AMPK signaling and changes in mTORC1 interaction. Journal of Cellular Biochemistry, pages n/a-n/a.
Crossref
Crossref